Clinical Trials on Refractory Gastroesophageal Reflux Disease in Hong Kong

Total 78 results

Chinese University of Hong Kong

Recruiting

Antireflux Mucosectomy (ARMS) for Treatment of Gastroesophageal Reflux (ARMS)

Gastro Esophageal Reflux

Hong Kong
Chinese University of Hong Kong

Unknown

A Prospective Randomized Trial Comparing Laparoscopic Nissen Against Anterior Partial Fundoplication in Treating Gastroesophageal Reflux Disease Among Chinese Patients

Gastroesophageal Reflux Disease

Hong Kong
Muhammad

Not yet recruiting

Effect of Lidocaine Block on Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Hong Kong
Chinese University of Hong Kong

Completed

Symptomatic Gastroesophageal Reflux Disease: Double Blind Randomized Controlled Study of On-demand Therapy Versus Maintenance Therapy

Gastroesophageal Reflux Disease

China
Chinese University of Hong Kong

Unknown

Translation and Validation of the PASS Test for GERD Patients With Partial Response to PPI: PASS-HK

Gastro-esophageal Reflux Disease

Hong Kong
Chinese University of Hong Kong

Completed

Functional Gastrointestinal Disorder Screening Program - A Randomized Controlled Trial (FGISP-RCT)

Functional Dyspepsia | Irritable Bowel Syndrome | Non-erosive Gastroesophageal Reflux Disease

Hong Kong
Chinese University of Hong Kong

Recruiting

Effect of Routine Anterior Crural Repair in De-Novo Gastroesophageal Reflux After Laparoscopic Sleeve Gastrectomy

Obesity | Gastro Esophageal Reflux Disease

China
Chinese University of Hong Kong

Recruiting

ARMA for Postoperative GERD After Sleeve Gastrectomy

Gastroesophageal Reflux

Hong Kong
Chinese University of Hong Kong

Completed

Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population

Gastroesophageal Reflux Disease

China
Hospital Authority, Hong Kong
The University of Hong Kong

Unknown

The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population

Gastroesophageal Reflux

China
Hospital Authority, Hong Kong
The University of Hong Kong

Unknown

A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study

Chest Pain

China
Chinese University of Hong Kong

Completed

BRAVO Study for Functional Dyspepsia (BD)

Dyspepsia | Gastroesophageal Reflux

Hong Kong
Chinese University of Hong Kong

Recruiting

Long Term Incidence and Effect of de Novo GERD After Laparoscopic Sleeve Gastrectomy in Chinese Population

Gastroesophageal Reflux

Hong Kong
Hospital Authority, Hong Kong
The University of Hong Kong

Completed

Prospective Double-blinded Randomized Controlled Trial of 12-weeks High Dose Rabeprazole (Pariet) in the Treatment of Reflux Laryngitis in Chinese Patients

Gastroesophageal Reflux | Laryngitis

China
Chinese University of Hong Kong

Terminated

The Role of Visceral Hyperalgesia, Gastroesophageal Reflux Disease (GERD) and Esophageal Motility Disorder (EMD) in NCCP Patients

Non-Cardiac Chest Pain

China
NovoCure GmbH
Zai Lab (Shanghai) Co., Ltd.

Unknown

Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Chemotherapy as First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma

Gastric Cancer | GastroEsophageal Cancer

Hong Kong
Chinese University of Hong Kong

Completed

Minimally Invasive Evaluation of Dyspepsia by Combined Magnetically Controlled Capsule Endoscopy and Urea Breath Test: a Pilot Prospective Cohort Study (MCUDYSPEPSIA)

Dyspepsia | Gastroesophageal Reflux | Peptic Ulcer Disease | Pancreatobiliary Disease | Ugi Malignancies

Hong Kong
Chinese University of Hong Kong

Completed

EUS-guided Glue Injection for Varices Study

Gastroesophageal Varices

Hong Kong
Chinese University of Hong Kong

Recruiting

The Use of AI to Improve Quality of OGD

Dyspepsia | Anemia | Dysphagia | Acid Reflux

Hong Kong
Takeda

Completed

Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

Hong Kong, Korea, Republic of, Taiwan
New Epsilon Innovation Limited

Active, not recruiting

An Early Phase Study of NEI-01 in Patients With Solid Tumors or Acute Myeloid Leukemia

Advanced Solid Tumor | Relapsed AML | Refractory AML

Hong Kong
AstraZeneca

Completed

Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.

Gastroesophageal Reflux Disease

Vietnam
Arbele Pty Ltd

Recruiting

Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients

Gastric Cancer | Pancreatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Gastrointestinal Cancer | Liver Cancer | Colorectal Adenocarcinoma | Gastroesophageal Junction

Hong Kong, Australia
National University Hospital, Singapore
Janssen, LP; International Myeloma Foundation

Unknown

Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma

Relapse and / or Refractory Myeloma

Singapore, Hong Kong, Taiwan, Korea, Republic of
National University Hospital, Singapore
Celgene; International Myeloma Foundation; The Australasian Leukaemia & Lymphoma...

Unknown

Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Relapsed and/or Refractory Multiple Myeloma

Singapore, Hong Kong, Korea, Republic of, Taiwan
Janssen Research & Development, LLC
Eisai Inc.

Completed

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

Gastroesophageal Reflux Disease (GERD)

United States, Poland, United Kingdom, Belgium, Brazil
Takeda

Completed

Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients

Gastroesophageal Reflux Disease | Heartburn

China
Braintree Laboratories

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

Non-erosive Reflux Disease

United States
Takeda

Completed

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
VA Office of Research and Development

Completed

A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

GERD

United States
AstraZeneca

Completed

ASTERIX: Low Dose ASA and Nexium

Gastroesophageal Reflux

Bulgaria, Italy, South Africa, Spain, Hungary, Canada, Hong Kong, Greece, Germany, Australia, United Kingdom
Takeda

Completed

Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341)

Gastroesophageal Reflux Disease (GERD)

United Kingdom, Australia, Belgium, Spain, Austria, Germany, Argentina, Brazil, Canada, France, Hong Kong, India, Italy, Korea, Republic of, Malaysia, Mexico, Poland, Portugal, Singapore, South Africa, Switzerland, Taiwan
Takeda

Completed

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
AstraZeneca

Completed

National Survey on Gastroesophageal Reflux Disease (GERD) Patients (LINEA)

GERD

France
Takeda

Completed

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Gastroesophageal Reflux

United States
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Active, not recruiting

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Recurrent Colon Carcinoma | Metastatic Colorectal Carcinoma | Stage IV Colon Cancer AJCC v7 | Stage IVA Colon Cancer AJCC v7 | Stage IVB Colon Cancer AJCC v7 | Refractory Colorectal Carcinoma

United States
Taiho Oncology, Inc.

Active, not recruiting

Futibatinib in Patients With Specific FGFR Aberrations

Advanced or Metastatic Solid Tumor | Advanced or Metastatic Gastric or Gastroesophageal Cancer | Myeloid or Lymphoid Neoplasms (MLN)

United States, Spain, Turkey, Hong Kong, Korea, Republic of, Belgium, Japan, Netherlands, France, Germany, Italy, Sweden, United Kingdom, Portugal, Singapore
Eisai Inc.

Completed

Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Refractory Partial Seizures

Hong Kong, Italy, Australia, Spain, Portugal, Taiwan, India, Thailand, Hungary, Poland, Bulgaria, Serbia, Russian Federation, Korea, Republic of, Ukraine, Romania, Latvia, Lithuania, Germany, Estonia, Czech Republic, Philippines, Ma...
Syndax Pharmaceuticals

Available

Expanded Access Program for SNDX-5613

Relapsed/Refractory Acute Leukemia

United States
AstraZeneca
Daiichi Sankyo Co., Ltd.

Completed

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens (DG-06)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation (REACH2)

Corticosteroid Refractory Acute Graft vs Host Disease

Germany, Japan, Saudi Arabia, Turkey, United Kingdom, Spain, Canada, Italy, Australia, Austria, France, Korea, Republic of, Hong Kong, Israel, Netherlands, Russian Federation, Denmark, Greece, Taiwan, Norway, Czechia, Bulgaria
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico, Australia
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649)

Gastric Cancer | Esophageal Adenocarcinoma | Gastroesophageal Junction Cancer

United States, Argentina, Australia, Brazil, Canada, Chile, China, Colombia, Czechia, France, Germany, Greece, Hong Kong, Hungary, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Portugal, Romania, Russian Federation, Si... and more
AstraZeneca

Recruiting

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Gastric Cancer | Gastroesophageal Junction Cancer

Canada, Spain, United Kingdom, China, France, Italy, Vietnam, Germany, United States, India, Taiwan, Thailand, Hong Kong, Japan, Switzerland, Poland
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico

Clinical Trials on Refractory Gastroesophageal Reflux Disease in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations